File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Continuous entecavir for treatment-naïve Chinese chronic hepatitis B in the real world setting: the six-year results

TitleContinuous entecavir for treatment-naïve Chinese chronic hepatitis B in the real world setting: the six-year results
Authors
Seto, WKLam, YFLiu, KSHMak, LYKo, MKLFung, JLai, CLYuen, RMF
KeywordsMedical sciences
Gastroenterology
Issue Date2014
PublisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro
Citation
The 2014 Gastroenterology Conference: Digestive Disease Week (DDW 2014), Chicago, IL., 3-6 May 2014. In Gastroenterology, 2014, v. 146 n. 5, suppl. 1, p. S963-S964, abstract Su1016 How to Cite?
DOI: http://dx.doi.org/10.1016/S0016-5085(14)63507-1
AbstractBACKGROUND: There is a paucity of data on uninterrupted entecavir for treatment-naive chronic hepatitis B (CHB) beyond 5 years. METHODS: Treatment-naive Chinese CHB patients were treated continuously with entecavir 0.5mg daily in the real world setting for up to 6 years. The cumulative rates of hepatitis B e antigen (HBeAg) seroconversion, alanine aminotransferase (ALT) normalization, DNA undetectability, virologic breakthrough (>1 log HBV DNA increase from the nadir) and genotypic resistance to entecavir were determined. HBV DNA levels were measured by Roche Taqman real time PCR assay (lower limit of detection: 20 IU/mL). Resistance profile was determined by line probe assay (LiPA, Innogenetics NV, Gent, Belgium) for patients ...
DescriptionThis journal suppl. entitled: 2014 DDW Abstract
Persistent Identifierhttp://hdl.handle.net/10722/198626
ISSN
0016-5085
2021 Impact Factor: 33.883
2020 SCImago Journal Rankings: 7.828
ISI Accession Number ID
WOS:000371236404611

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKen_US
dc.contributor.authorLam, YFen_US
dc.contributor.authorLiu, KSHen_US
dc.contributor.authorMak, LYen_US
dc.contributor.authorKo, MKLen_US
dc.contributor.authorFung, Jen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYuen, RMFen_US
dc.date.accessioned2014-07-07T08:14:45Z-
dc.date.available2014-07-07T08:14:45Z-
dc.date.issued2014en_US
dc.identifier.citationThe 2014 Gastroenterology Conference: Digestive Disease Week (DDW 2014), Chicago, IL., 3-6 May 2014. In Gastroenterology, 2014, v. 146 n. 5, suppl. 1, p. S963-S964, abstract Su1016en_US
dc.identifier.issn0016-5085-
dc.identifier.urihttp://hdl.handle.net/10722/198626-
dc.descriptionThis journal suppl. entitled: 2014 DDW Abstract-
dc.description.abstractBACKGROUND: There is a paucity of data on uninterrupted entecavir for treatment-naive chronic hepatitis B (CHB) beyond 5 years. METHODS: Treatment-naive Chinese CHB patients were treated continuously with entecavir 0.5mg daily in the real world setting for up to 6 years. The cumulative rates of hepatitis B e antigen (HBeAg) seroconversion, alanine aminotransferase (ALT) normalization, DNA undetectability, virologic breakthrough (>1 log HBV DNA increase from the nadir) and genotypic resistance to entecavir were determined. HBV DNA levels were measured by Roche Taqman real time PCR assay (lower limit of detection: 20 IU/mL). Resistance profile was determined by line probe assay (LiPA, Innogenetics NV, Gent, Belgium) for patients ...-
dc.languageengen_US
dc.publisherWB Saunders Co. The Journal's web site is located at http://www.elsevier.com/locate/gastro-
dc.relation.ispartofGastroenterologyen_US
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in Gastroenterology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Gastroenterology, v. 146 n. 5, suppl. 1, May 2014. DOI: 10.1016/S0016-5085(14)63507-1-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleContinuous entecavir for treatment-naïve Chinese chronic hepatitis B in the real world setting: the six-year resultsen_US
dc.typeConference_Paperen_US
dc.identifier.emailSeto, WK: wkseto2@hku.hken_US
dc.identifier.emailFung, J: jfung@hkucc.hku.hken_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailYuen, RMF: mfyuen@hku.hken_US
dc.identifier.authoritySeto, WK=rp01659en_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturepostprint-
dc.identifier.doi10.1016/S0016-5085(14)63507-1-
dc.identifier.hkuros229852en_US
dc.identifier.hkuros230714-
dc.identifier.volume146-
dc.identifier.issue5, suppl. 1-
dc.identifier.spageS963-
dc.identifier.epageS964-
dc.identifier.isiWOS:000371236404611-
dc.publisher.placeUnited States-
dc.identifier.issnl0016-5085-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats